Table 2.
Patterns of drug use in Scotland between 1 March 2020 and 10 November 2021
| n (%) | Overall* | Dexamethasone† | Remdesivir† | Tocilizumab† | More than one drug‡ |
| Scotland | |||||
| Total | 4063 | 3094 (76.2) | 68 (1.7) | 145 (3.6) | 756 (18.5) |
| March–June 2020 | 6 | 6 (100) | 0 | 0 | 0 |
| July–September 2020 | 31 | 21 (67.7) | 3 (9.7) | 0 | 7 (22.6) |
| October–December 2020 | 860 | 711 (82.7) | 45 (5.2) | 0 | 104 (12.1) |
| January–March 2021 | 1461 | 1203 (82.3) | 15 (1.0) | 55 (3.8) | 188 (12.9) |
| April–June 2021 | 290 | 199 (68.8) | 1 (0.3) | 16 (5.5) | 74 (25.5) |
| July–September 2021 | 1324 | 874 (66.0) | 4 (0.3) | 73 (5.5) | 373 (28.2) |
| October–November 2021§ | 91 | 80 (87.9) | 0 | 1 (1.1) | 10 (11.0) |
*Includes all patients treated with at least one of the drugs of interest during the study period; dates of inclusion of each drug in National Health Services treatment guidelines: remdesivir 29 May 2020; dexamethasone 16 June 2020; tocilizumab 8 January 2021.6–8
†Includes only patients treated exclusively with one of the drugs of interest.
‡Includes patients treated with two or more of the drugs of interest, in any combination/sequence.
§Includes patients admitted to hospital up to and including 10 November 2021.